Chardan lowered the firm’s price target on Editas Medicine (EDIT) to $3.50 from $12 and keeps a Buy rating on the shares. The firm updated its Editas model for Q3 results and progress on lead in vivo gen editing candidate EDIT-401. The firm noted the space’s pullback has created a buying opportunity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- FDA appoints Richard Pazdur as Director of CDER
- Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties
- Editas Medicine Reports Q3 2025 Progress and Financials
- Editas Medicine price target raised to $4.60 from $4 at Clear Street
- Editas Medicine reports Q3 EPS (28c), consensus (38c)